NCT03510520View on ClinicalTrials.gov

Comparison of MCO HD on Markers of Vascular Health Compared With On-Line Haemodiafiltration

NACompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

May 9, 2019

Study Completion Date

May 9, 2019

Conditions
End Stage Renal DiseaseCardiovascular DiseasesInflammation
Interventions
DEVICE

Medium Cut-Off Haemodialysis

Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months

DEVICE

On-Line Haemodiafiltration

Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)

Trial Locations (1)

M13 9WL

Manchester NHS Foundation Trust, Manchester

All Listed Sponsors
collaborator

Manchester Metropolitan University

OTHER

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Manchester University NHS Foundation Trust

OTHER_GOV

NCT03510520 - Comparison of MCO HD on Markers of Vascular Health Compared With On-Line Haemodiafiltration | Biotech Hunter | Biotech Hunter